Skip to content

5AM Venture Management, LLC

Follow

13F filer, CIK 1799883, SAN FRANCISCO, CA

5AM Venture Management, LLC reported $297,006,238 across 16 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 91.18% of the portfolio.

Accepted , ingested 13F-HR 0001799883-26-000004

Period
2026-09-30
Reported value
$297M
Holdings
16
Top 10 weight
91.18%
New
2
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LTGOnew+7,325,962$122M
SKYEnew+981,269$1.58M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PHVSreduced-317,700-$10.1M
SRZNexited-271,250-$7.04M
SKYEexited-9,681,763-$6.71M
CLDXreduced-75,000-$2.43M
CAMPreduced-591,875-$2.39M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001799883-26-000004, largest first. % of portfolio is the value over $297,006,238, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LTGOLATIGO BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 7,325,962 shares 7,325,962$122M41.19%newTimeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,408,379 shares; 2025Q1: 4,408,379 shares; 2025Q2: 4,308,379 shares; 2025Q3: 4,256,379 shares; 2025Q4: 4,056,379 shares; 2026Q1: 4,056,379 shares; 2026Q2: 4,056,379 shares; 2026Q3: 3,784,650 shares 3,784,650$24M8.09%-271,729Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 939,298 shares; 2025Q1: 939,298 shares; 2025Q2: 939,298 shares; 2025Q3: 939,298 shares; 2025Q4: 1,029,298 shares; 2026Q1: 1,029,298 shares; 2026Q2: 1,029,298 shares; 2026Q3: 1,029,298 shares 1,029,298$22.5M7.58%0Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,927,915 shares; 2025Q1: 2,927,915 shares; 2025Q2: 2,927,915 shares; 2025Q3: 5,869,091 shares; 2025Q4: 5,869,091 shares; 2026Q1: 5,869,091 shares; 2026Q2: 5,869,091 shares; 2026Q3: 5,277,216 shares 5,277,216$21.3M7.18%-591,875Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,353,304 shares; 2025Q1: 2,353,304 shares; 2025Q2: 2,353,304 shares; 2025Q3: 2,353,304 shares; 2025Q4: 2,353,304 shares; 2026Q1: 2,353,304 shares; 2026Q2: 2,353,304 shares; 2026Q3: 2,353,304 shares 2,353,304$16.8M5.64%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 797,600 shares; 2025Q1: 797,600 shares; 2025Q2: 797,600 shares; 2025Q3: 797,600 shares; 2025Q4: 797,600 shares; 2026Q1: 797,600 shares; 2026Q2: 797,600 shares; 2026Q3: 479,900 shares 479,900$15.2M5.13%-317,700Timeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 596,660 shares; 2025Q1: 511,660 shares; 2025Q2: 511,660 shares; 2025Q3: 511,660 shares; 2025Q4: 606,660 shares; 2026Q1: 606,660 shares; 2026Q2: 606,660 shares; 2026Q3: 606,660 shares 606,660$14.1M4.76%0Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 497,270 shares; 2025Q1: 497,270 shares; 2025Q2: 497,270 shares; 2025Q3: 497,270 shares; 2025Q4: 497,270 shares; 2026Q1: 497,270 shares; 2026Q2: 497,270 shares; 2026Q3: 422,270 shares 422,270$13.7M4.61%-75,000Timeline
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 490,000 shares; 2025Q1: 490,000 shares; 2025Q2: 490,000 shares; 2025Q3: 490,000 shares; 2025Q4: 3,947,913 shares; 2026Q1: 3,947,913 shares; 2026Q2: 3,947,913 shares; 2026Q3: 3,947,913 shares 3,947,913$10.9M3.68%0Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 478,972 shares; 2025Q1: 478,972 shares; 2025Q2: 478,972 shares; 2025Q3: 478,972 shares; 2025Q4: 738,972 shares; 2026Q1: 738,972 shares; 2026Q2: 738,972 shares; 2026Q3: 738,972 shares 738,972$9.87M3.32%0Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 950,011 shares; 2026Q1: 950,011 shares; 2026Q2: 950,011 shares; 2026Q3: 741,893 shares 741,893$7.56M2.55%-208,118Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 476,200 shares; 2025Q1: 476,200 shares; 2025Q2: 476,200 shares; 2025Q3: 476,200 shares; 2025Q4: 476,200 shares; 2026Q1: 476,200 shares; 2026Q2: 476,200 shares; 2026Q3: 476,200 shares 476,200$5.2M1.75%0Timeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,057,325 shares; 2026Q2: 3,057,325 shares; 2026Q3: 3,057,325 shares 3,057,325$4.25M1.43%0Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 800,000 shares; 2025Q1: 800,000 shares; 2025Q2: 800,000 shares; 2025Q3: 800,000 shares; 2025Q4: 1,369,782 shares; 2026Q1: 1,369,782 shares; 2026Q2: 1,369,782 shares; 2026Q3: 1,369,782 shares 1,369,782$4.18M1.41%0Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,050,000 shares; 2025Q1: 1,050,000 shares; 2025Q2: 1,050,000 shares; 2025Q3: 1,050,000 shares; 2025Q4: 1,050,000 shares; 2026Q1: 1,050,000 shares; 2026Q2: 1,050,000 shares; 2026Q3: 1,050,000 shares 1,050,000$3.43M1.16%0Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 981,269 shares 981,269$1.58M0.53%newTimeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SRZNSURROZEN INC271,250$7.04Mshares
SKYESKYE BIOSCIENCE INC9,681,763$6.71Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001799883-26-000004 base2026-11-16